PODCAST | The More Data We Have, the Better - CBER Director, US FDA

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), speaks with Chris Houchin, Partner at Guidehouse, in a video interview about the challenges and opportunities of using data sets for rare disease treatment, using decentralized trials, and the possibility of leveraging real-world evidence for cell and gene therapies, and partnering with the FDA.

There are no comments yet.

Please log in to write the first comment.